The Potential Predictive Role of Tumour Necrosis Factor-α, Interleukin-1β, and Monocyte Chemoattractant Protein-1 for COVID-19 Patients Survival

References

• Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255–2273. doi:10.1056/NEJMra2026131
   PubMed Web of Science ®Google Scholar
• Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–115. doi:10.1016/j.thromres.2020.06.029
   PubMed Web of Science ®Google Scholar
• Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–e47. doi:10.1016/S2213-2600(20)30216-2
   PubMed Web of Science ®Google Scholar
• Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75.
   PubMed Web of Science ®Google Scholar
• Darif D, Hammi I, Kihel A. The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog. 2021;153:104799. doi:10.1016/j.micpath.2021.104799
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, Ren L. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Bülow Anderberg S, Luther T, Berglund M, et al. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine. 2021;138:155389. doi:10.1016/j.cyto.2020.155389
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang J, Liu C, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26(1):97. doi:10.1186/s10020-020-00230-x
   PubMed Web of Science ®Google Scholar
• Leija-Martínez JJ, Huang F, Del-Río-Navarro BE, et al. IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19. Med Hypotheses. 2020;144:109935. doi:10.1016/j.mehy.2020.109935
   Web of Science ®Google Scholar
• Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. Int J Mol Sci. 2019;20(23):6008.
   PubMed Web of Science ®Google Scholar
• Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50(3):184–195.
   PubMed Web of Science ®Google Scholar
• Birra D, Benucci M, Landolfi L, et al. COVID 19: a clue from innate immunity. Immunol Res. 2020;68(3):161–168. doi:10.1007/s12026-020-09137-5
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27(6):992–1000.e3. doi:10.1016/j.chom.2020.04.009
   PubMed Web of Science ®Google Scholar
• Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020;509:280–287. doi:10.1016/j.cca.2020.06.017
   PubMed Web of Science ®Google Scholar
• Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. Postgrad Med J. 2020;96(1137):403–407. doi:10.1136/postgradmedj-2020-137935
   PubMed Web of Science ®Google Scholar
• Yang Y, Shen C, Li J, et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. Infect Dis. 2020. doi:10.1101/2020.03.02.20029975
   Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613.
   PubMed Web of Science ®Google Scholar
• Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428–e436.
   PubMedGoogle Scholar
• Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. doi:10.1089/jir.2008.0027
   PubMed Web of Science ®Google Scholar
• Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-A review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–732. doi:10.1080/22221751.2020.1746199
   PubMed Web of Science ®Google Scholar
• Lorkiewicz P, Waszkiewicz N. Biomarkers of Post-COVID Depression. J Clin Med. 2021;10(18):4142.
   PubMed Web of Science ®Google Scholar
• Coronavirus Disease 2019 (COVID-19) Treatment Guidelines; 2020. Available from: https://www.covid19treatmentguidelines.nih.gov/. Accessed 26 January 2022.
   Google Scholar
• Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–329.
   PubMed Web of Science ®Google Scholar
• Ni M, Tian FB, Xiang DD, Yu B. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19. J Med Virol. 2020;92(11):2600–2606. doi:10.1002/jmv.26070
   Web of Science ®Google Scholar
• Heriansyah T, Chomsy IN, Febrianda L, Farahiya Hadi T, Andri Wihastuti T. The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: a Literature Review. Sci Pharm. 2020;88(4):55. doi:10.3390/scipharm88040055
   Web of Science ®Google Scholar
• de la Rica R, Borges M, Gonzalez-Freire M. COVID-19: in the Eye of the Cytokine Storm. Front Immunol. 2020;11:1–11.
   Web of Science ®Google Scholar
• McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med. 2020;202(6):812–821.
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–1643.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446.
   PubMed Web of Science ®Google Scholar
• Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66–70. doi:10.1016/j.cytogfr.2020.05.002
   PubMed Web of Science ®Google Scholar
• Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020;92(10):2188–2192. doi:10.1002/jmv.26031
   PubMed Web of Science ®Google Scholar
• Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: the Current Evidence and Treatment Strategies. Front Immunol. 2020;11:1708.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. Author Correction: a new coronavirus associated with human respiratory disease in China. Nature. 2020;580(7803):E7.
   PubMed Web of Science ®Google Scholar
• Abers MS, Delmonte OM, Ricotta EE, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021;6(1):e144455.
   Web of Science ®Google Scholar